Sage Therapeutics

Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Its mission is to make life better for patients with central nervous systems diseases by discovering, developing, and delivering important new medicines to the market. SAGE’s lead program, SAGE-547, is in clinical development for super-refractory status epilepticus (SRSE) and is the first of many compounds the company is developing in its portfolio of potential seizure medicines. SAGE’s robust chemistry platform has generated multiple new compounds that target the GABAA and NMDA receptors, which have demonstrated preclinical activity. 

Company Growth (employees)
Type
Public
HQ
Cambridge, US
Founded
2010
Size (employees)
135 (est)+118%
Website
sagerx.com
Sage Therapeutics was founded in 2010 and is headquartered in Cambridge, US

Key People at Sage Therapeutics

Jeffrey Jonas

Jeffrey Jonas

Chief Executive Officer
Kimi Iguchi

Kimi Iguchi

CFO
Stephen Kanes

Stephen Kanes

Chief Medical Officer
Albert J. Robichaud

Albert J. Robichaud

CSO
Thomas Anderson

Thomas Anderson

Chief Commercial Strategy Officer
Jim Doherty

Jim Doherty

Vice President of Pharmacology, Head of Biology

Sage Therapeutics Office Locations

Sage Therapeutics has an office in Cambridge
Cambridge, US (HQ)
215 First Street

Sage Therapeutics Data and Metrics

Sage Therapeutics Financial Metrics

$, USD

Net income (FY, 2016)

(159 m)

EBIT (FY, 2016)

(160.2 m)

Market capitalization (22-Jun-2017)

3.2 b

Closing share price (22-Jun-2017)

83.3

Cash (31-Dec-2016)

168.5 m
Sage Therapeutics's current market capitalization is $3.2 b.
$, USDFY, 2014FY, 2015FY, 2016

R&D expense

24.1 m69.4 m120.8 m

General and administrative expense

9.7 m25.3 m39.4 m

Operating expense total

33.8 m94.7 m160.2 m

EBIT

(33.8 m)(94.7 m)(160.2 m)

Interest expense

8 k

Interest income

8 k

Net Income

(33.8 m)(94.5 m)(159 m)
$, USDFY, 2014FY, 2015FY, 2016

Cash

127.8 m186.8 m168.5 m

Inventories

1.1 m1.7 m5.1 m

Current Assets

128.8 m188.5 m402.6 m

PP&E

163 k286 k1.4 m

Total Assets

129.7 m189 m404.5 m

Accounts Payable

2.4 m5.2 m12.8 m

Current Liabilities

7.8 m15.3 m35.2 m

Additional Paid-in Capital

188.7 m335 m689 m

Retained Earnings

(66.8 m)(161.3 m)(320.3 m)

Total Equity

121.9 m173.7 m368.5 m

Financial Leverage

1.1 x1.1 x1.1 x
$, USDFY, 2014FY, 2015FY, 2016

Net Income

(33.8 m)(94.5 m)(159 m)

Depreciation and Amortization

51 k115 k281 k

Inventories

(715 k)(681 k)(3.4 m)

Accounts Payable

441 k2.7 m7.8 m

Cash From Operating Activities

119.7 m59 m(118.7 m)

Purchases of PP&E

(128 k)(198 k)(1.4 m)

Cash From Investing Activities

(128 k)(198 k)(230.5 m)

Cash From Financing Activities

146.9 m129.9 m331 m
Y, 2016

Financial Leverage

1.1 x

Sage Therapeutics Market Value History

Sage Therapeutics Online and Social Media Presence

Sage Therapeutics News and Updates

Sage Therapeutics Company Life and Culture

You may also be interested in